- Home
- CAPR vs AMRN Comparison
CAPR vs AMRN Comparison
Compare CAPR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- AMRN
- Stock Information
- Founded
- CAPR 2005
- AMRN 1989
- Country
- CAPR United States
- AMRN Ireland
- Employees
- CAPR N/A
- AMRN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- AMRN Health Care
- Exchange
- CAPR Nasdaq
- AMRN Nasdaq
- Market Cap
- CAPR 324.6M
- AMRN 339.8M
- IPO Year
- CAPR N/A
- AMRN 1993
- Fundamental
- Price
- CAPR $4.66
- AMRN $15.93
- Analyst Decision
- CAPR Strong Buy
- AMRN Strong Sell
- Analyst Count
- CAPR 6
- AMRN 1
- Target Price
- CAPR $23.17
- AMRN $12.00
- AVG Volume (30 Days)
- CAPR 1.9M
- AMRN 109.8K
- Earning Date
- CAPR 11-10-2025
- AMRN 10-29-2025
- Dividend Yield
- CAPR N/A
- AMRN N/A
- EPS Growth
- CAPR N/A
- AMRN N/A
- EPS
- CAPR N/A
- AMRN N/A
- Revenue
- CAPR $11,130,509.00
- AMRN $226,733,000.00
- Revenue This Year
- CAPR N/A
- AMRN N/A
- Revenue Next Year
- CAPR $7,894.07
- AMRN N/A
- P/E Ratio
- CAPR N/A
- AMRN N/A
- Revenue Growth
- CAPR N/A
- AMRN N/A
- 52 Week Low
- CAPR $4.40
- AMRN $7.08
- 52 Week High
- CAPR $20.75
- AMRN $20.90
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- AMRN 41.03
- Support Level
- CAPR $5.52
- AMRN $15.74
- Resistance Level
- CAPR $6.01
- AMRN $17.25
- Average True Range (ATR)
- CAPR 0.49
- AMRN 0.71
- MACD
- CAPR -0.06
- AMRN 0.04
- Stochastic Oscillator
- CAPR 12.42
- AMRN 40.64
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.